Tevogen Bio is a clinical-stage specialty immunotherapy company headquartered in New Jersey, United States, focused on developing precision T-cell therapies designed to address large unmet medical needs. The company leverages its proprietary ExacTcell™ platform, which harnesses CD8+ cytotoxic T lymphocytes to create off-the-shelf, genetically unmodified T-cell therapies targeting diseased cells while preserving healthy tissue.

Founded in 2020, Tevogen Bio aims to develop cost-effective personalised immunotherapies and improve patient access to advanced cell therapies. The company’s platform supports applications across multiple therapeutic areas, including oncology, infectious diseases and neurology, enabling the development of precision therapies for large patient populations.

Tevogen Bio combines immunotherapy expertise with artificial intelligence capabilities through its Tevogen.AI initiative, which uses predictive technologies to accelerate drug discovery and improve development efficiency. The company is focused on reducing development timelines and improving affordability for next-generation immunotherapies.

The organisation is driven by a team of experienced biopharmaceutical leaders and scientists, and has advanced its lead programmes rapidly, moving one product from discovery to clinical phase within approximately 18 months—significantly faster than traditional development timelines.

Key products and services

Precision T-cell immunotherapy platform

• ExacTcell™ proprietary precision T-cell technology
• Off-the-shelf, genetically unmodified T-cell therapies
• Targeted therapies designed to preserve healthy cells

Clinical-stage therapeutic pipeline

• Oncology programmes
• Infectious disease therapies
• Neurology and immunology applications
• Multi-indication immunotherapy development

Artificial intelligence-enabled drug discovery

• Tevogen.AI predictive drug development platform
• Proteome prediction and target discovery
• Accelerated candidate identification and optimisation

Cell therapy research and development

• Precision immunotherapy design
• Clinical development support
• Translational research and biomarker development

Integrated biotechnology development model

• Discovery-to-clinical development support
• Precision medicine platform development
• Pipeline expansion across therapeutic areas

By combining precision immunotherapy, artificial intelligence and an affordability-focused business model, Tevogen Bio aims to expand access to advanced cell therapies and accelerate development timelines. Its proprietary technology platform and multi-indication pipeline position the company as an emerging innovator in next-generation immunotherapy and precision medicine.